- Home
- HTOO vs KZIA Comparison
HTOO vs KZIA Comparison
Compare HTOO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTOO
- KZIA
- Stock Information
- Founded
- HTOO 2020
- KZIA 1994
- Country
- HTOO Ireland
- KZIA Australia
- Employees
- HTOO N/A
- KZIA N/A
- Industry
- HTOO Natural Gas Distribution
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- HTOO Utilities
- KZIA Health Care
- Exchange
- HTOO Nasdaq
- KZIA Nasdaq
- Market Cap
- HTOO 7.7M
- KZIA 9.0M
- IPO Year
- HTOO N/A
- KZIA 1999
- Fundamental
- Price
- HTOO $4.73
- KZIA $7.08
- Analyst Decision
- HTOO
- KZIA Strong Buy
- Analyst Count
- HTOO 0
- KZIA 3
- Target Price
- HTOO N/A
- KZIA $16.00
- AVG Volume (30 Days)
- HTOO 393.5K
- KZIA 302.5K
- Earning Date
- HTOO 02-28-2023
- KZIA 11-14-2025
- Dividend Yield
- HTOO N/A
- KZIA N/A
- EPS Growth
- HTOO N/A
- KZIA N/A
- EPS
- HTOO N/A
- KZIA N/A
- Revenue
- HTOO $10,024,662.00
- KZIA $1,549,158.00
- Revenue This Year
- HTOO $4,832.46
- KZIA N/A
- Revenue Next Year
- HTOO $81.82
- KZIA $49.25
- P/E Ratio
- HTOO N/A
- KZIA N/A
- Revenue Growth
- HTOO 105.98
- KZIA 248983.08
- 52 Week Low
- HTOO $3.41
- KZIA $2.86
- 52 Week High
- HTOO $30.45
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- HTOO 51.49
- KZIA 44.58
- Support Level
- HTOO $4.57
- KZIA $6.74
- Resistance Level
- HTOO $5.42
- KZIA $8.00
- Average True Range (ATR)
- HTOO 0.49
- KZIA 0.50
- MACD
- HTOO 0.01
- KZIA -0.01
- Stochastic Oscillator
- HTOO 40.95
- KZIA 50.56
About HTOO Fusion Fuel Green PLC
Fusion Fuel Green PLC is a provider of full-service energy engineering and advisory solutions, specializing in green hydrogen and industrial gas applications. It offers a broad portfolio of services, including the design, supply, installation, and maintenance of energy systems, as well as the transport and distribution of liquefied petroleum gas. The company serves a diverse customer base spanning commercial buildings, mixed-use developments, heavy industries, and food service sectors. The group currently derives revenue by providing comprehensive solutions for the liquefied petroleum gas (LPG) industry, which includes the supply, installation, and maintenance of LPG systems, as well as transportation and delivery of LPG in both bulk and cylinder formats.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.